The TROV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TROV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The TROV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View TROV Detailed Price Forecast - CNN Money||View TROV Detailed Summary - Google Finance|
|View TROV Detailed Summary - Yahoo! Finance||View TROV Stock Research & Analysis - Zacks.com|
|View TROV Trends & Analysis - Trade-Ideas||View TROV Major Holders - Barrons|
|View TROV Call Transcripts - NASDAQ||View TROV Breaking News & Analysis - Seeking Alpha|
|View TROV Annual Report - CompanySpotlight.com||View TROV OTC Short Report - OTCShortReport.com|
|View TROV Fundamentals - TradeKing||View TROV SEC Filings - Bar Chart|
|View Historical Prices for TROV - The WSJ||View Performance/Total Return for TROV - Morningstar|
|View the Analyst Estimates for TROV - MarketWatch||View the Earnings History for TROV - CNBC|
|View the TROV Earnings - StockMarketWatch||View TROV Buy or Sell Recommendations - MacroAxis|
|View the TROV Bullish Patterns - American Bulls||View TROV Short Pain Metrics - ShortPainBot.com|
|View TROV Stock Mentions - StockTwits||View TROV Stock Mentions - PennyStockTweets|
|View TROV Stock Mentions - Twitter||View TROV Investment Forum News - Investor Hub|
|View TROV Stock Mentions - Yahoo! Message Board||View TROV Stock Mentions - Seeking Alpha|
|View Insider Transactions for TROV - SECform4.com||View Insider Transactions for TROV - Insider Cow|
|View TROV Major Holdings Summary - CNBC||View Insider Disclosure for TROV - OTC Markets|
|View Insider Transactions for TROV - Yahoo! Finance||View Institutional Holdings for TROV - NASDAQ|
|View TROV Stock Insight & Charts - FinViz.com||View TROV Investment Charts - StockCharts.com|
|View TROV Stock Overview & Charts - BarChart||View TROV User Generated Charts - Trading View|
Is TrovaGene Inc (NASDAQ:TROV) A Healthcare Industry Laggard Or Leader?
Posted on Tuesday September 18, 2018
TrovaGene Inc (NASDAQ:TROV), a US$14.2m small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as anRead More...
Trovagene Announces Participation at The MicroCap Conference on October 1st and 2nd at the Essex House in New York City
Posted on Tuesday September 18, 2018
SAN DIEGO, Sept. 18, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, today announced it will be featured as a presenting company at The MicroCap Conference that is being held on October 1st and 2nd, 2018 at the Essex House in New York City. Dr. Thomas Adams, Executive Chairman of Trovagene, Inc., will provide an overview of the Company, the current status of ongoing clinical trials in Acute Myeloid Leukemia (AML) and metastatic Castration-Resistant Prostate Cancer (mCRPC), as well as anticipated near-term milestones, during the live presentation on October 2nd at 10:30 AM eastern time. Dr. Adams and Dr. Mark Erlander, Chief Scientific Officer, will also be available to participate in one-on-one meetings with investors who are registered to attend the conference, on Monday, October 1st and Tuesday, October 2nd.
SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that the European Commission (EC) has endorsed the positive opinion of the Committee for Orphan Medicinal Products (COMP) and has granted Orphan Drug Designation (ODD) for Onvansertib, a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the treatment of patients with Acute Myeloid Leukemia (AML). "The European Commission's decision to grant orphan drug designation to Onvanersertib for the treatment of AML is a key regulatory milestone that will further facilitate our clinical development program," said Dr. Thomas Adams, Executive Chairman of Trovagene.
Trovagene Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018
Posted on Thursday August 23, 2018
SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies for the treatment of leukemias, lymphomas and solid tumor cancers, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Dr. Thomas Adams, Executive Chairman of Trovagene, Inc., will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.